

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

\*FHK- Florida Healthy Kids

## Non-Preferred Topical Agents for External Anogenital Warts Step Therapy

Override(s)	Approval Duration
Prior Authorization	16 weeks

Medications	Comments
imiquimod 5 % cream	Preferred
podofilox 0.5% solution (requires prior authorization)	
Condylox 0.5% gel	Non-Preferred
brand Condylox 0.5% solution	
Veregen 15% ointment	

### **APPROVAL CRITERIA**

Requests for podofilox agents (Condylox gel, solution; podofilox solution) may be approved if the following criteria is met:

- I. Individual is using topically to treat external anogenital warts caused by human papillomavirus (HPV) (Label, CDC 2015); **OR**
- II. Individual is using topically to treat molluscum contagiosum (AHFS)

### **AND**

Requests for a non-preferred topical agent (Codylox gel, solution, Veregen ointment) for external anogenital warts may be approved if the following criteria is met:

- I. Individual has had a trial and inadequate response or intolerance to generic imiquimod 5 % cream **OR** generic podofilox 0.5% solution;

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

\*FHK- Florida Healthy Kids

Podofilox agents (Condylox gel, solution; podofilox solution) may not be approved for the following:

- I. Treatment of mucous membrane warts.

Note: The safety and effectiveness of podofilox agents have not been established for treatment beyond 16-weeks or for multiple treatment courses.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

**Key References:**

1. Centers for Disease Control and Prevention. 2015 Sexually Transmitted Diseases Treatment Guidelines – Anogenital Warts. Available from: <http://www.cdc.gov/std/tg2015/warts.htm>. Last reviewed/updated: June 4, 2015. Accessed on: August 27, 2018.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: August 27, 2018.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.